Yehuda Handelsman to Male
This is a "connection" page, showing publications Yehuda Handelsman has written about Male.
Connection Strength
1.198
-
Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clin Cardiol. 2019 Mar; 42(3):391-399.
Score: 0.095
-
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes. Diabetes Obes Metab. 2019 04; 21(4):883-892.
Score: 0.094
-
How does CKD affect HbA1c? J Diabetes. 2018 Apr; 10(4):270.
Score: 0.087
-
Lipid-lowering efficacy and safety of alirocumab in patients with or without diabetes: A sub-analysis of ODYSSEY COMBO II. Diabetes Obes Metab. 2017 07; 19(7):989-996.
Score: 0.083
-
Diabetes treatment over age 65: Is worse control really better? J Diabetes. 2017 May; 9(5):428-430.
Score: 0.083
-
Lorcaserin treatment allows for decreased number needed to treat for weight and glycemic parameters in week 12 responders with =5% weight loss. Postgrad Med. 2016 Nov; 128(8):740-746.
Score: 0.081
-
SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT? Endocr Pract. 2015 Dec; 21(12):1442-4.
Score: 0.075
-
Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014 Oct; 37(10):2723-30.
Score: 0.069
-
Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract. 2010 Jul-Aug; 16(4):617-28.
Score: 0.052
-
Colesevelam HCl improves fasting plasma glucose and lipid levels in patients with prediabetes. Postgrad Med. 2009 Nov; 121(6):62-9.
Score: 0.050
-
Metabolic syndrome pathophysiology and clinical presentation. Toxicol Pathol. 2009 Jan; 37(1):18-20.
Score: 0.047
-
Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial. Diabetes Care. 2025 Sep 01; 48(9):1512-1516.
Score: 0.037
-
Intense simplified strategy for newly diagnosed type 2 diabetes in patients with severe hyperglycaemia: multicentre, open label, randomised trial. BMJ. 2024 10 15; 387:e080122.
Score: 0.035
-
Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristone. BMJ Open. 2024 07 16; 14(7):e081121.
Score: 0.034
-
Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26?Weeks Treatment. Endocr Pract. 2024 Sep; 30(9):810-816.
Score: 0.034
-
Efficacy and safety of evolocumab in individuals with type 2 diabetes mellitus: primary results of the randomised controlled BANTING study. Diabetologia. 2019 06; 62(6):948-958.
Score: 0.024
-
Propensity-score-matched comparative analyses of simultaneously administered fixed-ratio insulin glargine 100?U and lixisenatide (iGlarLixi) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes. Diabetes Obes Metab. 2018 12; 20(12):2821-2829.
Score: 0.023
-
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017 12; 5(12):941-950.
Score: 0.021
-
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. JAMA. 2017 Jul 04; 318(1):45-56.
Score: 0.021
-
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD-ON). Diabetes Obes Metab. 2014 Jul; 16(7):636-44.
Score: 0.017
-
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012 Dec; 35(12):2464-71.
Score: 0.015
-
Initial combination therapy with metformin plus colesevelam in drug-na?ve Hispanic patients with early type 2 diabetes. Postgrad Med. 2012 Jul; 124(4):7-13.
Score: 0.015
-
Clinical effects of colesevelam in Hispanic subjects with primary hyperlipidemia and prediabetes. Postgrad Med. 2012 Jul; 124(4):14-20.
Score: 0.015
-
American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: executive summary. Endocr Pract. 2012 Mar-Apr; 18(2):269-93.
Score: 0.015
-
American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012 Mar-Apr; 18 Suppl 1:1-78.
Score: 0.015
-
Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US. J Diabetes. 2011 Mar; 3(1):67-73.
Score: 0.014
-
Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010 Jul-Aug; 16(4):629-40.
Score: 0.013
-
Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence. Diabetes Obes Metab. 2010 May; 12(5):384-92.
Score: 0.013
-
Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract. 2010 Jan-Feb; 16(1):53-63.
Score: 0.013
-
American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract. 2003 May-Jun; 9(3):237-52.
Score: 0.008